Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 10/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.42 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.40 |
| ▸ | CHRNG | P07510 | 2/20 | 0.40 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.40 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.40 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | CHRND | Q07001 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22654437 | 1.00 | SLC6A4 (0.42) | SLC6A4SLC6A3SLC6A2CHRNA1CHRNG | |
| SCHEMBL21236191 | 1.00 | SLC6A4 (0.42) | SLC6A4SLC6A3SLC6A2CHRNA1CHRNG | |
| SCHEMBL20073952 | 0.87 | SLC6A4 (0.41) | SLC6A4SLC6A3SLC6A2CHRNA1CHRNG | |
| SCHEMBL21236206 | 0.84 | SLC6A3 (0.53) | SLC6A4SLC6A3SLC6A2CHRNA1CHRNG | |
| SCHEMBL18198499 | 0.84 | SLC6A4 (0.37) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL20817354 | 0.83 | KDM1A (0.45) | SLC6A4SLC6A3SLC6A2CHRNA1CHRNG | |
| SCHEMBL21236589 | 0.80 | SLC6A2 (0.40) | SLC6A4SLC6A2 | |
| SCHEMBL22654409 | 0.80 | SLC6A2 (0.40) | SLC6A4SLC6A2 | |
| SCHEMBL21236593 | 0.80 | SLC6A2 (0.40) | SLC6A4SLC6A2 | |
| SCHEMBL28111403 | 0.80 | SLC6A2 (0.42) | SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3746444-B1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2023-09-27 | — | — | EP | disclosed |
| US-11491157-B2 | Cycloalkyl substituted pyrazolopyrimidines having activity against RSV | Janssen Sciences Ireland Unlimited Company Co Cork, IE (IE) | 2022-11-08 | — | — | US | disclosed |
| US-20200360387-A1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | JANSSEN-CILAG (FR) | 2020-11-19 | — | — | US | disclosed |
| US-20200360387-A1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | JANSSEN-CILAG (FR) | 2020-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200360387-A1 | CYCLOALKYL SUBSTITUTED PYRAZOLOPYRIMIDINES HAVING ACTIVITY AGAINST RSV | ACE, ACE2, PTBP1 | SLC6A4 4203/4885SLC6A3 4789/4885SLC6A2 4651/4885 |
| US-11491157-B2 | Cycloalkyl substituted pyrazolopyrimidines having activity against RSV | ACE, ACE2, PTBP1 | SLC6A4 4155/4885SLC6A3 4766/4885SLC6A2 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.